These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23211539)

  • 1. Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas.
    Ajeawung NF; Wang HY; Kamnasaran D
    Cancer Lett; 2013 Apr; 330(2):130-40. PubMed ID: 23211539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas.
    Sutter R; Shakhova O; Bhagat H; Behesti H; Sutter C; Penkar S; Santuccione A; Bernays R; Heppner FL; Schüller U; Grotzer M; Moch H; Schraml P; Marino S
    Oncogene; 2010 Mar; 29(12):1845-56. PubMed ID: 20062081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in molecular targets for the treatment of medulloblastomas.
    Ajeawung NF; Wang HY; Gould P; Kamnasaran D
    Clin Invest Med; 2012 Oct; 35(5):E246. PubMed ID: 23043706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous hematopoietic stem cell transplantation for pediatric solid tumors.
    Hale GA
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):835-46. PubMed ID: 16221053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
    Ridola V; Grill J; Doz F; Gentet JC; Frappaz D; Raquin MA; Habrand JL; Sainte-Rose C; Valteau-Couanet D; Kalifa C
    Cancer; 2007 Jul; 110(1):156-63. PubMed ID: 17541945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas.
    Abe M; Tokumaru S; Tabuchi K; Kida Y; Takagi M; Imamura J
    Pediatr Neurosurg; 2006; 42(2):81-8. PubMed ID: 16465076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
    Pizer BL; Clifford SC
    Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastomas.
    Sutton LN; Packer RJ; Schut L
    Neurosurg Clin N Am; 1990 Jan; 1(1):97-109. PubMed ID: 2135976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medulloblastomas: update on a heterogeneous disease.
    Bourdeaut F; Miquel C; Alapetite C; Roujeau T; Doz F
    Curr Opin Oncol; 2011 Nov; 23(6):630-7. PubMed ID: 21892087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted chemotherapy in childhood medulloblastoma.
    Varan A
    Expert Rev Anticancer Ther; 2011 May; 11(5):771-80. PubMed ID: 21554052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Past, current and future protocols for combined modality therapy in childhood medulloblastoma.
    Kaaijk P; Schouten-van Meeteren AY; Slotman BJ; Kaspers GJ
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):79-90. PubMed ID: 12597352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.
    Beutler D; Avoledo P; Reubi JC; Mäcke HR; Müller-Brand J; Merlo A; Kühne T
    Cancer; 2005 Feb; 103(4):869-73. PubMed ID: 15641034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.
    Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG
    Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management of medulloblastoma in adults.
    Eisenstat DD
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):795-802. PubMed ID: 15485314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.